The b
The biotech house of the broader healthcare sector outperformed others within the last quarter of 2019, due to elevated mergers & acquisitions, constructive regulatory backdrop and stable trial outcomes. Higher-than-expected company earnings added to this energy.
M&A Wave
The most recent to leap on the M&A bandwagon is Sarepta Therapeutics SRPT, which entered right into a licensing settlement with Roche RHHBY for its lead gene remedy candidate, SRP-9001, to deal with Duchenne muscular dystrophy (DMD) outdoors the USA for $1.15 billion. In the meantime, Merck & Co. MRK and Sanofi SNY agreed to purchase smaller cancer-drug makers ArQule ARQL and Synthorx THOR, respectively (learn: Biotech ETFs Hit New Highs on Deal Activities).
Lat month, Swiss drugmaker Novartis NVS agreed to merge with The Medicines Firm in a $9.7-billion deal.
Regulatory & Trial Outcome
Within the newest rounds of reports, Sarepta Therapeutics rallied after the Meals and Drug Administration authorized Vyondys 53 for muscular dystrophy remedy. Strong Biosciences SLDB spiked following the examine of two sufferers who obtained doses of its experimental DMD remedy, which confirmed that the remedy “has the potential” to profit them.
Aurinia Prescribed drugs AUPH…